louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00011154: Exogenous Toxicants and Genetic Susceptibility in ALS
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Amyotrophic Lateral Sclerosis
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS)
Sponsor class: NIH
First posted: 2001-02-14
Enrollment: 525
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurodegenerative disease that poses a significant burden for affected individuals and their family members. The principal objective of this epidemiologic study is to identify environmental and genetic risk factors for ALS. Of primary interest is whether environmental chemicals such as heavy metals, pesticides and organic solvents contribute to the cause of ALS. We also aim to identify genetic factors that contribute to the risk of ALS because individuals with certain genetic traits may be unable to protect against the toxic effects of chemical exposure. Other factors that may protect against the development of ALS, such as dietary antioxidants, are also under investigation. If modifiable factors affecting the risk for ALS could be identified, interventions to delay or even prevent the development of ALS could be developed.

Detailed description: The principal objective of this study is to identify environmental and/or genetic risk factors for amyotrophic lateral sclerosis (ALS). We are addressing this objective by conducting a case-control study of ALS in the Northern California Kaiser Permanente Medical Care Program (KPMCP). Over a four-year period, approximately 175 persons newly diagnosed with ALS will be identified and recruited through physician referrals and computerized mechanisms available within the Kaiser system. The patients with ALS will be compared to a sample of 350 age- and gender-matched persons without ALS from the same membership. Specific study aims are as follows: (1) to investigate the association of ALS with exposure to neurotoxicants including lead, other heavy metals, solvents and pesticides; (2) to determine whether inadequate oxidative defenses for protecting against free-radicals enhance the toxicity of exogenous exposures; (3) to examine the evidence for familial aggregation of neurodegenerative diseases among first-degree relatives of patients with ALS; and (4) to estimate the incidence of ALS in diverse racial and ethnic groups.

Eligibility criteria: Individuals with ALS within the Kaiser Permanente population of Northern California, ages 18 years and older, with first diagnosis of ALS in the years 1996-2000.

Controls are individuals who are age- and sex-matched to the patients with ALS, also from the Kaiser Permanente population.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01641354: Comparison of Two Surgical Techniques to Treat Knock Knees in Children
Official title: Reversible Hemiepiphysiodesis in Children - Stapling Versus Eight Plate
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Genu Valgus
Keywords: Hemiepiphysiodesis
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2012-07-16
Enrollment: 14
Sex: ALL
Minimum age (years): 8
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Knock knees or genu valgus necessitates in some children corrective surgery with partial closure of the growth plate at level of the knee.

Detailed description: Background: Genu valgus is a condition with malalignment of the lower extremity. Surgery may be indicated in severe cases and reversible hemiepiphysiodesis is often the treatment of choice in growing children. Partial closure can be obtained by stapling technique or with a new treatment called tension band plating.

Eligibility criteria: Inclusion Criteria:

* genu valgus
* remaining growth

Exclusion Criteria:

* systemic disease
* unilateral disease

Primary outcomes:
measure: Treatment time
timeFrame: up to 3 years
Secondary outcomes:
measure: Pain score post operatively
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
Study officials:
References:
citation: Gottliebsen M, Rahbek O, Hvid I, Davidsen M, Hellfritzsch MB, Moller-Madsen B. Hemiepiphysiodesis: similar treatment time for tension-band plating and for stapling: a randomized clinical trial on guided growth for idiopathic genu valgum. Acta Orthop. 2013 Apr;84(2):202-6. doi: 10.3109/17453674.2013.782526. Epub 2013 Mar 14.
Clinical trial NCT06927154: Comparison of Facet Oscillatory Mobilization and Mobilization With Movement in Chronic Mechanical Neck Pain
Official title: Comparison of Facet Oscillatory Mobilization and Mobilization With Movement in Chronic Mechanical Neck Pain
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Chronic Mechanical Neck Pain
Keywords: Chronic Mechanical Neck Pain
Facet Oscillatory Mobilization
Mobilization with Movement (MWM)
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2025-04-15
Enrollment: 32
Sex: ALL
Minimum age (years): 35
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study compares Facet Oscillatory Mobilization and Mobilization with Movement in managing chronic mechanical neck pain, aiming to determine the effectiveness of these techniques in pain, range of motion, and disability.

Detailed description: This study will be Conducted as a randomized controlled trial, it will include 32 participants divided into two groups receiving different mobilization techniques along with conventional physical therapy. Outcome measures such as the Numeric Pain Rating Scale (NPRS), Neck Disability Index (NDI), and Inclinometer will be used to assess changes over a two-week intervention period with a follow-up after one month.

Eligibility criteria: Inclusion Criteria:

* complaint of Chronic Mechanical neck pain ( more than 6 weeks).
* Neck Disability Index (NDI) score more than 16%
* Age between 35-45 years, Both Male and Female
* NPRS score more than 3-6.
* Recurrent neck pain aggravated at least once in the month.
* Painful Cervical ROM (Flexion less than 80, Extension less than 70, rotation less than 90 to both sides and lateral flexion less than 35 degree.

Exclusion Criteria:

* Cervical radiculopathy
* Cervical canal stenosis
* Severe neurological disorder
* Previous cervical surgery
* Recent history of fall/trauma to the cervical spine.

Primary outcomes:
measure: Numeric pain rating scale (NPRS)
timeFrame: Four Weeks
measure: Inclinometer
timeFrame: Four Weeks
measure: Neck Disability Index (NDI)
timeFrame: Four Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chakdara
country: Pakistan
facility: Riphah International University, Malakand
state: KPK
Study officials:
affiliation: Riphah International University
name: Amnah Anum, MSPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01279954: Abatacept in the Treatment of Uveitis
Official title: An Openlabel, Phase II Trial of Abatacept (Orencia) in the Treatment of Refractory Non-infectious Uveitis.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Uveitis
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
First posted: 2011-01-20
Enrollment: 10
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety and efficacy of abatacept in the treatment of uveitis.


Eligibility criteria: Inclusion Criteria:

* patients with vision-threatening autoimmune uveitis
* failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects

Exclusion Criteria:

* serious concomitant illness that could interfere with the subject's participation

Primary outcomes:
measure: Adverse Events
timeFrame: 2 years
Secondary outcomes:
measure: Number of Participants With Improvement by 2 or More Lines of Best-corrected Visual Acuity
timeFrame: Week 24
measure: Number of Participants With Reduction in Systemic Corticosteroid or Other Immunosuppressive Therapy by at Least 50%
timeFrame: Week 24
measure: Number of Participants With Control of Ocular Inflammation, as Judged on Clinical Criteria, According to Standard Methods
timeFrame: Week 24
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
affiliation: Oregon Health and Science University
name: Eric B. Suhler, MD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Oregon Health and Science University
name: James T Rosenbaum, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00641433: Topical Collagen-Silver Versus Standard Care Following Removal of Ingrown Nails
Official title: Topical Collagen-Silver Versus Standard Care Following Phenol Ablation of Ingrown Nails: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Ingrown Nail
Keywords: chemocautery
Lead sponsor: Rosalind Franklin University of Medicine and Science
Sponsor class: OTHER
First posted: 2008-03-24
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study's purpose is to prospectively determine whether topical therapy with an oxidized regenerated cellulose collagen-silver compound is more effective than the current standard of topical antibiotic therapy for care following the removal of an ingrown toenail. Eighty adult patients with ingrown toenails will be recruited. Each patient will randomly be assigned to apply either topical silver sulfadiazine cream (standard antibiotic) or the novel collagen-silver compound to their nail bed daily, following removal of the ingrown portion of nail. Patients will return for follow up visits weekly, until healing has occurred or twelve weeks have passed. Healing will be defined as resolution of drainage and inflammatory changes surrounding the nail border.


Eligibility criteria: Inclusion Criteria:

* Ingrown toenails will be defined as any incurvated nail border that digs into the skin of the nail fold and causes pain and discomfort

Exclusion Criteria:

* Patients with immunocompromised states

  * chronic steroid use
  * diabetes mellitus
  * collagen vascular disease
  * HIV infection
* Cellulitis proximal to the hallux interphalangeal joint or peripheral vascular disease will be excluded
* We will define peripheral vascular disease as the absence of one or more pedal pulses or the presence of dystrophic changes to the integument

Primary outcomes:
measure: time to healing
timeFrame: weekly
Secondary outcomes:
measure: time to return to regular shoe gear
timeFrame: weekly
measure: days unable to work
timeFrame: weekly
Other outcomes:
Locations:
city: North Chicago
country: United States
facility: Scholl Foot and Ankle Center
state: Illinois
city: Roanoke
country: United States
facility: Preofessional Education and Research Institutue
state: Virginia
Study officials:
affiliation: Rosalind Franklin University
name: David G Armstrong, DPM, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06338033: Prognostic Study of Visceral Fat and Heart Failure With Preserved Ejection Fraction
Official title: Prognostic Study of Visceral Fat and Heart Failure With Preserved Ejection Fraction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Failure With Preserved Ejection Fraction and Visceral Fat
Lead sponsor: Chongqing Medical University
Sponsor class: OTHER
First posted: 2024-03-29
Enrollment: 298
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Heart failure with preserved ejection fraction(HFpEF)

Brief summary: Obesity and heart failure with preserved ejection fraction (HFpEF) have multiple pathologic associations that affect the prognosis of HFpEF. Chinese people are more prone to visceral obesity, resulting in varying degrees of true obesity in individuals with the same body mass index (BMI). There are no prognostic studies of VFA/BMI in the HFpEF population.

Detailed description: A total of 298 patients with HFpEF who were hospitalized in the Department of Cardiovascular Medicine of the First Affiliated Hospital of Chongqing Medical University from September 2020 to August 2023 were included in this prospective cohort study.All patients were followed up on November 30, 2023.The primary endpoint of the study was all-cause mortality and secondary endpoints were rehospitalization for heart failure and composite endpoints of both.After a median follow-up of 564 days, a total of 30 (10.1%) patients died and 82 (27.5%) were rehospitalized for heart failure. Patients with HFpEF were categorized into two groups according to median VFA/BMI (VFA/BMI \<5.49; VFA/BMI ≥5.49).The aim of this study was to elucidate whether VFA/BMI has prognostic value in patients with HFpEF by Kaplan-Meier survival analysis and cox regression analysis.

Eligibility criteria: Inclusion Criteria:

* Adule aged≥18 years old;
* Diagnosed with HFpEF.

Diagnostic criteria including:

1. left ventricular ejection fraction ≥50%;
2. with signs and/or symptoms of heart failure;
3. Sinus rhythm：BNP≥35pg/mL and/or NT-proBNP≥125pg/mL;Atrial fibrillation rhythm：BNP≥105pg/mL and/or NT-proBNP≥365pg/mL；
4. at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction.

Exclusion Criteria:

* Age ≤18 years;
* malignant tumor;
* comorbid severe hepatic and/or renal insufficiency;
* lost to follow-up.

Primary outcomes:
measure: All-cause mortality
timeFrame: November 30, 2023
Secondary outcomes:
measure: Rehospitalization for heart failure
timeFrame: November 30, 2023
Other outcomes:
measure: Composite endpoints of all-cause mortality and rehospitalization for heart failure
timeFrame: November 30, 2023
Locations:
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
Study officials:
affiliation: First Affiliated Hospital of Chongqing Medical University
name: Dongying Zhang, doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT05230433: High-fat Meal Challenge in Pediatrics
Official title: Implications of Insulin Resistance and Cardiorespiratory Fitness in the Metabolic Response to a High-fat Meal Challenge in Pediatrics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pediatric Obesity
Insulin Resistance
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
First posted: 2022-02-09
Enrollment: 15
Sex: ALL
Minimum age (years): 8
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The objective is to determine if how physical fitness, measured using a treadmill maximal oxidative capacity test, is associated with the capacity to metabolize a high-fat meal in pediatrics (ages 8-17 years). Ability to metabolize the meal will be assessed by profiling mitochondrial and extra-mitochondrial fatty acid metabolites. The investigators will test if fatty acid oxidation mediates the relationship between fitness and markers of metabolic health, such as insulin resistance.


Eligibility criteria: Inclusion Criteria:

* Children ages 8-17 years with a BMI-percentile ≥ 5th.

Exclusion Criteria:

* Previous diagnosis of type 1 or 2 diabetes.
* Use of concurrent medications known to affect glucose metabolism (metformin, oral steroids, sulfonylureas, insulin).
* Evidence of inherited disorders of lipid metabolism.
* Inability to participant in the maximal aerobic capacity test on the treadmill.
* Allergies to palm oils or protein types within high-fat challenge, such as lactose and soy.
* Individuals who cannot speak and/or write in English.

Primary outcomes:
measure: Determine if the interaction between daily physical activity and dietary intake mediates the correlation between VO2 max and body composition - as measured by daily physical activity.
timeFrame: Up to 7 days
measure: Determine if the interaction between daily physical activity and dietary intake mediates the correlation between VO2 max and body composition - as measured by daily dietary intake.
timeFrame: Up to 7 days
measure: Determine if the interaction between daily physical activity and dietary intake mediates the correlation between VO2 max and body composition - as measured by VO2 max.
timeFrame: Up to 7 days
measure: Determine if the interaction between daily physical activity and dietary intake mediates the correlation between VO2 max and body composition - as measured by body composition.
timeFrame: Up to 7 days
Secondary outcomes:
measure: Assess the correlation between fatty acid oxidation and VO2 max.
timeFrame: Five blood draws (fasting, 30 minutes, 60 minutes, 120 minutes, and 180 minutes) all completed on 1 day
Other outcomes:
measure: Assess if fatty acid oxidation mediates the correlation between VO2 max and a continuous metabolic syndrome score.
timeFrame: Five blood draws (fasting, 30 minutes, 60 minutes, 120 minutes, and 180 minutes) all completed on 1 day
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Health
state: New Hampshire
Study officials:
References:
Clinical trial NCT00316433: Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer
Official title: Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Small Cell Lung Cancer
Lead sponsor: Swedish Medical Center
Sponsor class: OTHER
Collaborators: name: Sanofi-Synthelabo
First posted: 2006-04-20
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.


Eligibility criteria: Inclusion Criteria:

* Previously untreated extensive small cell lung cancer
* No prior chemotherapy
* No prior radiotherapy except for the treatment of brain metastases

Exclusion Criteria:

* Prior treatment for extensive stage small cell lung cancer
* Known hypersensitivity to any of the components of oxaliplatin or CPT-11
* Greater than grade 2 peripheral neuropathy
* Known HIV or Hepatitis B or C (active, previously treated or both)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Swedish Medical Center Cancer Institute
state: Washington
Study officials:
affiliation: Swedish Medical Center Cancer Institute
name: Howard (Jack) West, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00642733: A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Official title: An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Overall Survival and Disease Progression in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Pancreatic Cancer
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2008-03-25
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This single arm study will assess the efficacy and safety of Tarceva + gemcitabine in patients with locally advanced, unresectable or metastatic pancreatic cancer. Patients will receive Tarceva 100mg po daily, in combination with gemcitabine 1000mg/m2 iv weekly for 8 weeks, followed by weekly for 3 weeks of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.


Eligibility criteria: Inclusion Criteria:

* adult patients, \>=18 years of age;
* pancreatic cancer, surgically unresectable or with metastases;
* no previous chemotherapy (except concomitant with radiotherapy);
* ECOG 0-2.

Exclusion Criteria:

* pancreatic cancer without histologic or cytologic confirmation;
* surgical resection possible;
* previous chemotherapy not concomitant with radiotherapy;
* ECOG 3-4.

Primary outcomes:
measure: Overall survival; time to progression
timeFrame: 6 months
Secondary outcomes:
measure: Duration of response; disease-free survival
timeFrame: Event driven
measure: AEs, lab parameters
timeFrame: Throughout study
Other outcomes:
Locations:
city: Morelia
country: Mexico
city: Tijuana
country: Mexico
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References: